SI-BONE stock holds near mid-range as analysts signal upside

Published on 09/18/2026 at 20:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SI-BONE stock closed at USD 18.04 on Nasdaq on September 17, 2026, sitting roughly one third below the USD 24.17 consensus analyst price target. Recent ratings point to a Moderate Buy stance with seven firms covering the minimally profitable medtech specialist.

SIBN, US8255921098, Illustration mit AI erstellt.

SI-BONE, Inc. stock (ISIN US8255921098) finished Nasdaq trading at USD 18.04 on September 17, 2026, leaving the minimally profitable medtech company valued at about USD 800.07 million and trading in the middle of its 52-week range between USD 11.48 and USD 21.89 as of that date.

Analysts see upside for SI-BONE stock

According to MarketBeat on September 17, 2026, SI-BONE currently carries a consensus rating of Moderate Buy based on seven analyst opinions, including six Buy recommendations and one Sell, with no Hold ratings reported for the stock.

The same overview from MarketBeat indicates an average analyst price target of USD 24.17, implying about 34.0 percent upside compared with the USD 18.04 closing price on September 17, 2026 and framing the shares as having room to rise if growth expectations are met.

Recent trading and valuation metrics

Per data compiled by MarketBeat, SI-BONE shares traded in a daily range between USD 17.95 and USD 18.86 on September 17, 2026, with volume of 595,338 shares versus an average of 548,905 shares, signalling slightly elevated activity relative to the recent norm.

The same dataset from MarketBeat shows that SI-BONE stock has moved between a 52-week low of USD 11.48 and a 52-week high of USD 21.89, placing the September 17, 2026 closing level roughly USD 6.56 above the low and USD 3.85 below the high, a positioning that suggests the shares are neither at a bargain trough nor at a peak valuation.

On the same date, SI-BONE's market capitalization stood at USD 800.07 million according to MarketBeat, and the trailing twelve month earnings per share figure was negative at around minus USD 0.34, underscoring that the company is still loss-making on a net basis despite investor expectations for future growth.

Stock level offers measured risk-reward

For investors assessing SI-BONE stock around mid September 2026, the roughly 34.0 percent gap between the USD 18.04 closing price on September 17, 2026 and the USD 24.17 average analyst price target reported by MarketBeat represents a quantified upside scenario that is tied to continued adoption of its sacroiliac joint fusion technology and improved profitability.

At the same time, the negative trailing twelve month earnings per share of about minus USD 0.34 cited by MarketBeat highlights an important risk factor: SI-BONE must convert revenue into sustainable net income to justify higher valuation multiples over the medium term.

Closing stock snapshot

As of the completed trading session on September 17, 2026, SI-BONE stock closed at USD 18.04 on Nasdaq, representing a daily decline of USD 0.50 or 2.70 percent compared with the prior close and leaving the shares trading below the consensus analyst price target while remaining positioned in the mid-range of their 52-week high and low.